Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia

Study Overview
=================
Brief Summary
-----------------
The aim of the present study was to investigate the efficacy of aripiprazole in management of pre-existing neuroleptic-induced tardive dyskinesia

Detailed Description
-----------------
Objective:A few case reports on the use of aripiprazole in neuroleptic-induced tardive dyskinesia have demonstrated positive effects. However its effectiveness in treatment of TD was still inconclusive. The aim of the present study was to investigate the efficacy of aripiprazole in management of pre-existing neuroleptic-induced tardive dyskinesia. Method: Subjects with pre-existing neuroleptic-induced tardive dyskinesia were chosen from Taoyuan psychiatric center. Patients recruited would be treated with aripiprazole for cross-titration with previous antipsychotics in 8 weeks. We use AIMS, SAS, & BAS to assess the severity of TF and EPS. We record subjects' age, sex, and other factors which have influence at the treatment response. Subjects are assessed every two weeks in the first month and then monthly until six months.

Official Title
-----------------
Aripiprazole for Pre-Existing Neuroleptic-Induced Tardive Dyskinesia: a Prospective 26-Week Observational Study

Conditions
-----------------
Dyskinesia, Drug-Induced

Intervention / Treatment
-----------------
* Drug: aripiprazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female patients must agree to prevent from being pregnant during trial periods Meet psychotic disorder or mood disorder criteria of DSM-IV Patients must have psychiatric diseases that need to use antipsychotics for a long time They must meet DSM-IV research criteria for neuroleptics induce tardive dyskinesia No clinical significant major systemic diseases No special neurological diseases which would influence the assessment for EPS or TD Mentality is better than mild mental retardation Patients or .legal representatives agree to join in the research and sign informed consent. Exclusion Criteria: Unstable major systemic diseases Had neurological disorder influenced to EPS assessment Substance abuse or dependence other then coffee or tobacco within 6 months before study
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: aripiprazole|Flexible dose: 5-30 mg/day|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total scores of AIMS |  | The change from baseline to study endpoint | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total scores of PANSS |  | The change from baseline to study endpoint | 
| Total scores of SAS |  | The change from baseline to study endpoint | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
aripiprazole, Tardive Dyskinesia